![](/img/cover-not-exists.png)
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Bois, Andreas du, Kristensen, Gunnar, Ray-Coquard, Isabelle, Reuss, Alexander, Pignata, Sandro, Colombo, Nicoletta, Denison, Ursula, Vergote, Ignace, del Campo, Jose M, Ottevanger, Petronella, HeubnerLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/s1470-2045(15)00366-6
Date:
November, 2015
File:
PDF, 402 KB
english, 2015